Other languages Repligen Corporation

Equities

RGEN

US7599161095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
150.4 ^USD	+0.85%		-4.94%	-16.38%

Jun. 03	Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing	CI
May. 30	Transcript : Repligen Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 08:40 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing	Jun. 03
Repligen Insider Sold Shares Worth $3,377,283, According to a Recent SEC Filing	May. 22
Repligen's Q1 Adjusted Earnings, Revenue Fall	May. 01
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024	May. 01
Repligen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01
Repligen Corporation Appoints Maggie A. Pax as Board of Directors	Mar. 19
Repligen Insider Sold Shares Worth $681,348, According to a Recent SEC Filing	Mar. 13
Repligen Insider Sold Shares Worth $3,298,632, According to a Recent SEC Filing	Mar. 12
Repligen Insider Sold Shares Worth $866,204, According to a Recent SEC Filing	Feb. 27
Aktien Frankfurt Schluss: Dax stabil vor Zahlen des Trendsetters Nvidia	Feb. 21
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	Feb. 21
Sector Update: Health Care	Feb. 21
Aktien Frankfurt: Dax-Rekordhoch vor Nvidia-Zahlen wieder in Sicht	Feb. 21
Repligen Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance; Shares Fall Premarket	Feb. 21
Sartorius fällt - Ausblick von Repligen enttäuscht	Feb. 21
Repligen Corporation Provides Earnings Guidance for the Year 2024	Feb. 21
Repligen Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21
Repligen Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21
Stocks Decline Pre-Bell as Fed Outlook, Rates Weigh; Asia Mixed, Europe Mostly Up	Feb. 21
Repligen to Seek Acquisitions	Dec. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Repligen Corporation

Equities

RGEN

US7599161095

Other languages

Filters